<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03686384</url>
  </required_header>
  <id_info>
    <org_study_id>CLEAR-1</org_study_id>
    <nct_id>NCT03686384</nct_id>
  </id_info>
  <brief_title>SVT-15652 Otic Solution for the Treatment of Otomycosis</brief_title>
  <official_title>A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Assess the Efficacy and Safety of SVT-15652 Otic Solution Compared to Placebo for the Treatment of Fungal Otitis Externa (Otomycosis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Salvat</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Salvat</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, randomized, 2-arm parallel-group, double blind, placebo-controlled study in
      patients suffering from Otomycosis. This study will compare the efficacy and safety of
      SVT-15652 otic solution to that of Placebo, when administering one vial twice daily during 14
      days.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Therapeutical cure</measure>
    <time_frame>Test of cure on day 24</time_frame>
    <description>Proportion of subjects with therapeutic cure</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">191</enrollment>
  <condition>Otomycosis</condition>
  <arm_group>
    <arm_group_label>SVT-15652</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 vial twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 vial twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SVT-15652</intervention_name>
    <description>1 vial twice daily</description>
    <arm_group_label>SVT-15652</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 vial twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  At least 18 years of age

          -  Clinical diagnosis of otomycosis in one or both ears, where topical treatment is
             indicated.

          -  Signs/symptoms of pruritus, otalgia and ear fullness.

          -  Debris or drainage clinically consistent with fungal infection.

        Main Exclusion Criteria:

          -  Known bacterial otitis externa or malignant otitis externa.

          -  Tympanic perforation, tympanostomy tubes inserted and post mastoid surgery.

          -  Structural ear anomalies which may difficult the evaluation of the therapeutic
             response.

          -  Uncontrolled diabetes mellitus.

          -  Any infection requiring systemic antimicrobial or systemic antifungal therapy.

          -  Concomitant medicines that may interfere with the study evaluations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Enrique Jim√©nez, MD</last_name>
    <phone>+34 933946400</phone>
    <email>ejimenzv@svt.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Carolina Ear,Nose and Throat Clinic</name>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 20, 2018</study_first_submitted>
  <study_first_submitted_qc>September 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2018</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Otomycosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

